Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06451523 · ClinicalTrials.gov registry record · NA

Effects of "Alliance180 Program" on Well-Being

A NA study of Trauma and Stressor Related Disorders, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
2
Study locations

NCT06451523: Recruiting NA study of Trauma and Stressor Related Disorders, sponsored by University of North Carolina, Chapel Hill.

NCT06451523 is a NA study of Trauma and Stressor Related Disorders that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 50 participants, below the 61-participant average among 9 other Trauma and Stressor Related Disorders trials with a reported enrollment target (18% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06451523, a NA study of Trauma and Stressor Related Disorders, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to evaluate the effects of the Alliance180 Program on physical and psychological well-being on adults who are/were US Veterans, First Responders and/or Front Line Healthcare Workers. The study aims are: * Aim #1: to evaluate the effect of the Alliance180 Program on physical and psychological well-being in adults who are/were US Veterans, First Responders and/or Front Line Healthcare Workers; * Aim #2: to evaluate the relationship between between feelings of safety and well-being, autonomic functioning, and mental health indices (depression, anxiety, trauma response) before and after the intervention. Participants will be asked to complete self-report measures of feelings of safety and well-being, autonomic functioning, and mental health indices (depression, anxiety, trauma response) before participating in the Alliance180 Program (i.e., baseline research session) and 1 week, 1 month, 3 months and 6 months after completing the Alliance180 Program. Demographic information will be documented during the baseline research session.

Primary Outcome

The Anxiety Subscale of the Hospital Anxiety and Depression Scale (HADS) is a 7-item self-report questionnaire measuring the frequency of anxiety over the prior week. The anxiety subscale ranges from 0 to 21, with higher scores indicating higher anxiety complaints. Repeated measures ANOVA will be used to evaluate significant differences in change scores using a 0.05 significance level.

Interventions

  • OTHER Alliance180 Program

Study Locations (2)

New York

  • Alliance180 - Saratoga Springs

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-06-24
Est. Completion 2026-09
Phase NA

What NCT06451523 shows while recruiting

NCT06451523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 61-participant average among 9 other Trauma and Stressor Related Disorders trials with a reported enrollment target (18% lower).

The record links to 1 condition, with Trauma and Stressor Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Alliance180 Program is the first listed.

NCT06451523 reports a single indexed study location in New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06451523 about?

NCT06451523 is a clinical study titled "Effects of "Alliance180 Program" on Well-Being". The goal of this clinical trial is to evaluate the effects of the Alliance180 Program on physical and psychological well-being on adults who are/were US Veterans, First Responders and/or Front Line Healthcare Workers. The study aims are: * Aim #1: to evaluate the effect of the Alliance180 Program ...

What is the current status of trial NCT06451523?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-06-24. Estimated completion is 2026-09.

What conditions does trial NCT06451523 study?

This clinical trial studies the following conditions: Trauma and Stressor Related Disorders.

What interventions are being tested in trial NCT06451523?

The interventions under investigation include: Alliance180 Program (OTHER).

Who is sponsoring clinical trial NCT06451523?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06451523 being conducted?

This trial has 2 study locations across New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trauma and Stressor Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06451523's enrollment target sits among peer trials

50 4th of 9 higher than 6 of 9 other Trauma and Stressor Related Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Trauma and Stressor Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06451523, the US trial registry maintained by the National Library of Medicine. NCT06451523 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.